Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)


Hepatocellular carcinoma(HCC) is a high malignancy cancer which progress rapidly , and the rates of morbidity and mortality is very high in China. Radiotherapy as a effective treatment is commonly used in unresectable HCC patients. Preclinical models have shown that anti-angiogenesis medicine,such as rh-endostatin, can normalize the tumor vasculature to make it more efficient for oxygen delivery, which can enhance the radiosensitivity subsequently. This study is to evaluate the safety and efficacy of rh-endostatin combined with radiotherapy in the treatment of HCC.

Full Title of Study: “A Phase II Trial Of Rh-Endostatin In Combination With Radiotherapy In The Treatment Of Hepatocellular Carcinoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2018


  • Drug: recombinant human endostatin
    • The cycles of rh-endostatin’s treatment depends on the effect of reaction and tolerance.

Arms, Groups and Cohorts

  • Experimental: rh-endostatin combination
    • Continuous intravenous pumping (CIP) recombinant human endostatin(rh-endostatin) 30mg/d, from 5 days before radiotherapy,for 7days,21 per cycle.Standard radiotherapy for HCC is conducted concurrently.Those patients will receive 3-5 cycles rh-endostatin after the radiotherapy is finished,4-6 cycles in all.

Clinical Trial Outcome Measures

Primary Measures

  • progress-free survival(PFS)
    • Time Frame: 18 months
    • Progression Free Survival is defined as the time from enrollment to the date of first documented disease progression or death from any cause

Secondary Measures

  • response rate(RR)
    • Time Frame: 18months
    • CR(complete response)+PR(partial response)
  • clinical benefit rate(CBR)
    • Time Frame: 24months
    • CR+PR+SD(stable disease)
  • overall survival(OS)
    • Time Frame: 36 months
    • Overall survival was defined as the time from randomization to death from any cause.
  • adverse event(AE)
    • Time Frame: 36 months
    • Progression Free Survival is defined as the time from enrollment to the date of first documented disease progression or death from any cause
  • Quality of life (QOL)
    • Time Frame: 36months
    • A questionnaire with questions referred to simple assessments of physical abilities

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically or cytologically confirmed hepatocellular carcinoma,or radiographic indicative HCC with AFP>250ug/l – Inoperable and untransplantable,Child-pugh score A or B – PS score 0-1 – At least one measurable site(diameter >20mm measured by CT or MRI,>10mm measured by helical CT scan. – No distant metastases – Life expectancy longer than 3 months – Willingness and ability to comply the study and signed informed consent. Exclusion Criteria:

  • Not comply the designed treatment or change to other treatment – Miss follow-up visits or have incomplete follow-up data – The efficacy will not be assessed if the Patient withdrawal the treatment due to severe adverse events(SAE),but SAE will be recorded. – Disease progression – Patients request to withdraw – Patients with III hematologic or Ⅳ nonhematologic drug related toxicity ,or SAE

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Chinese PLA General Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: YuLi, Vice Director of Department of Radiotherappy – Chinese PLA General Hospital
  • Overall Official(s)
    • Yu Li, MD, Principal Investigator, China PLA hospital
  • Overall Contact(s)
    • Yu Li, MD, +86 15801570739,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.